Doxyral 50%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxyral 50%

Property Description
Active ingredient Doxycycline (as Doxycycline Hyclate)
Form Water-soluble powder
Pharmacological class Tetracycline-class antibacterial
Common use Systemic control of bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is Doxyral 50%?

Doxyral 50% is a specialized veterinary pharmaceutical preparation whose active compound, doxycycline, is a tetracycline-class antibacterial drug. This classification aligns it with the established group of broad-spectrum antibiotics. The product is supplied as a water-soluble powder containing a precise 50% concentration of the active compound. This formulation distinguishes it as a high-density preparation suitable for efficient oral administration through integration into the drinking water or milk intended for target animal species.


Doxycycline: Composition and Origin

The central active ingredient is doxycycline, typically stabilized in the readily soluble salt form, doxycycline hyclate. Doxycycline is formally known as a semi-synthetic second-generation tetracycline derivative, a compound produced via chemical modification of the natural substance oxytetracycline. This modification yields attributes such as increased lipophilicity (fat solubility), an attribute recognized for enhancing its systemic absorption and distribution.


What is the General Purpose of Doxyral?

The overall purpose of Doxyral is to provide effective control and containment against a wide range of susceptible bacterial infections within the host system. The doxycycline functions as a potent bacteriostatic agent by intervening directly in microbial cell processes. Its fundamental mechanism of effect involves inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit. This action stops the infection from escalating further, thereby reducing the microbial load and supporting the host's immune defenses.

Regulatory References

  1. Doxycycline Hyclate - StatPearls - NCBI Bookshelf (NIH)

What side effects are possible with Doxyral 50%?

The safety profile of doxycycline, the active substance in Doxyral 50%, is formally defined by government regulatory agencies based on frequency and physiological system involvement. All reported adverse effects and safety characteristics are derived exclusively from mandated prescribing information.

Officially Listed Adverse Reactions

Adverse events are categorized by frequency, reflecting how often they occur in clinical use. Reactions classified as Common often involve the Gastrointestinal System, including nausea and vomiting. Other common effects include photosensitivity reactions and various skin rashes. Uncommon effects include dyspepsia, while Rare adverse effects involve multiple systems, such as the Hepatobiliary System (e.g., hepatic failure, hepatitis) and the Nervous System (e.g., benign intracranial hypertension).

Serious Safety Considerations

Official labeling emphasizes Serious Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, due to their potential severity. Another serious concern is the risk of Clostridium difficile-Associated Diarrhea (CDAD), which has been reported to occur even months after the medicine is administered.

Population-Specific Constraints

As a characteristic of the tetracycline class, the substance presents specific safety constraints regarding Pediatric and Fetal Development. Use during the period of tooth formation (up to approximately 8 years of age) may result in permanent discoloration of the teeth and enamel hypoplasia. Furthermore, the drug is contraindicated in individuals with known hypersensitivity to any tetracycline-class compound.

Overdose and Emergency Response

Overdose Manifestations and Complications

Regulatory documentation indicates that an overdose of Doxycycline, the active ingredient in Doxyral 50%, may present as an exaggeration of documented dose-related effects, including severe gastrointestinal distress (nausea, vomiting, diarrhea) and exaggerated photosensitivity upon sun exposure. A specific neurological manifestation is Intracranial Hypertension (Pseudotumor Cerebri), signaled by severe headache, blurred vision, or double vision. Potential severe outcomes include life-threatening systemic complications such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and severe skin reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Permanent visual loss is a documented complication associated with persistent Intracranial Hypertension.

When to Seek Immediate Medical Help

The official labeling mandates that immediate medical attention be sought for life-threatening symptoms such as difficulty breathing, swelling of the face or throat, or the onset of painful, blistering skin reactions. The substance must be discontinued immediately if symptoms of Intracranial Hypertension or severe skin reactions are recognized. Management is generally symptomatic and supportive; standard procedures like hemodialysis are not effective for removal. A prompt ophthalmologic evaluation is warranted if any visual disturbance occurs. Furthermore, specific warnings note the risk of permanent tooth discoloration with exposure in children under eight years of age.

Therapeutic Uses of Doxyral 50%

What Doxyral 50% treats: main uses and benefits

Doxyral 50% is commonly used for the systemic control of bacterial infections, applied across domains where additional symptomatic support is needed for conditions primarily affecting the respiratory tract and gastrointestinal system. Specifically, the medication may be part of symptomatic management for conditions such as Chronic Respiratory Disease (CRD), bacterial pneumonias, colibacillosis (E. coli), and salmonellosis. The active substance is indicated for the treatment of infections of these systems.

The use of Doxyral 50% is relevant in clinical settings that involve acute or unstable symptom patterns, such as during herd or flock outbreaks. The treatment plays a role in managing the infection, which is considered relevant for easing respiratory distress and assisting with maintaining functional stability in the gut. Furthermore, it is commonly used to address infections caused by specific pathogens like Mycoplasma, Chlamydia, and *Rickettsia.

“The treatment provides symptomatic support during difficult episodes and assists with managing manifestations when symptoms are more noticeable.”

This systemic action assists with managing the bacterial presence, providing support that helps ease the overall symptom burden in relevant animal groups such as calves, pigs, and poultry during symptomatic phases.

Quick Fact: Support for Symptom Management
Doxyral 50% is commonly used in conditions presenting with systemic discomfort, offering supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. European Medicines Agency (EMA) documentation on Doxycycline

Eligibility and Restrictions for Use

The eligibility profile for Doxyral 50% (Doxycycline Hyclate) is governed by specific regulatory exclusions and restrictions.

Absolute Contraindications

The medicine is strictly contraindicated for individuals with a known hypersensitivity or allergy to Doxycycline or any other medicine in the tetracycline class of antibiotics. It must not be used concurrently with the drug isotretinoin due to a defined risk of developing intracranial hypertension.

Age- and Physiological Restrictions

Use is contraindicated in children under the age of eight years. This restriction is due to the potential for permanent dental discoloration and enamel hypoplasia during development. Exceptions are only permitted in severe, life-threatening infections, such as anthrax or Rocky Mountain spotted fever, where alternative treatments are unavailable and the potential benefits outweigh the risks. Adults and adolescents (aged 12 years and older) are eligible for standard use.

Pregnancy and Lactation: The medicine is contraindicated in women during the last half of pregnancy and is generally not recommended while nursing due to the drug's effect on fetal bone development and its excretion into human milk.

Condition-Specific Rules

Patients with impaired renal (kidney) function typically do not require dosage modification. However, caution is required when prescribing the medicine to patients with impaired hepatic (liver) function; severe liver disturbance is cited as an absolute contraindication in some regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Doxycycline are formally documented within government regulatory sources, focusing primarily on reduced drug exposure and potential potentiation of effects from co-administered substances.

Documented Interaction Classes

The most significant interactions involve chelation-based impaired absorption and enzyme induction that alters the drug's metabolic clearance. Co-administration with certain Retinoids is officially documented as a contraindicated combination due to the risk of benign intracranial hypertension (pseudotumor cerebri).

Interacting Substance/Class Official Interaction Outcome
Antacids, Iron, Bismuth Reduced Doxycycline absorption due to chelation.
Barbiturates, Phenytoin, Carbamazepine Decreased Doxycycline plasma half-life due to hepatic enzyme induction.
Anticoagulants (e.g., Warfarin) Potential for depressed plasma prothrombin activity, requiring dosage consideration for the anticoagulant.
Penicillin Co-administration should be avoided as tetracyclines may interfere with bactericidal action.

Timing and Population Considerations

To mitigate chelation effects, regulatory guidance advises that administration of substances containing divalent or trivalent cations (e.g., calcium, iron, magnesium) must be separated by several hours from the Doxycycline dose. Furthermore, Doxycycline administration requires caution in individuals with documented hepatic impairment, as noted in the Summary of Product Characteristics (SmPC). Chronic alcohol consumption may also decrease the drug's half-life.

Mechanism of Action

How Doxyral 50% Works

The mechanism of action for Doxyral 50% is defined by its two principal pharmacological domains: microbial growth inhibition and host pathway modulation.


Targeting Bacterial Growth via Ribosomal Inhibition

This domain covers the drug's primary action: interfering with the core biological machinery of susceptible bacteria. The drug binds reversibly to the 30S ribosomal subunit, which is essential for translating genetic code into proteins. This specific binding event inhibits the attachment of transfer RNA (tRNA), stopping the elongation of the peptide chain. The resulting inhibition of protein synthesis halts the growth and replication of the bacterial population, which functionally results in a bacteriostatic effect on the microbial population.


️ Modulating Host Proteolytic and Inflammatory Enzymes

This secondary domain involves the drug's direct influence on host pathology, independent of its effect on bacteria. The drug acts as an inhibitor of Matrix Metalloproteinases (MMPs), host enzymes that are upregulated during inflammation and mediate the degradation of connective tissue. By suppressing MMP activity and reducing the signaling of key pro-inflammatory cytokines, the drug modulates relevant inflammatory pathways. This mechanism reduces the enzymatic degradation of the extracellular matrix and affects pathways that mediate tissue breakdown.

Dosage and Administration Information

How Doxyral 50% is Used: Administration Principles

Doxyral 50% is formulated as a water-soluble powder intended for oral administration, delivered by dissolving the 500 mg/ g formulation into the animal’s drinking water or milk replacer. Use protocol is defined by weight-based dosing calculations.


Dosage and Frequency Patterns

The required daily amount of Doxyral 50% is determined by the target species and its body weight. For pigs and pre-ruminating calves, the standard regimen is 10 mg of Doxycycline Hyclate per kg of body weight per day. A higher dose of 25 mg per kg of body weight per day is designated for chickens (poultry).

The administration frequency is specific to the animal group. For pigs and poultry, the full calculated daily dose is generally consumed once daily via the medicated water. Conversely, for pre-ruminating calves, the daily dose is typically divided into two administrations, incorporated into their milk replacer. The standard duration of treatment across all approved species ranges from 3 to 5 consecutive days.


Preparation and Constraints

To ensure proper administration, the medicated solution must be freshly prepared every 24 hours. Standard procedures involve the use of suitably calibrated weighing equipment to accurately measure the precise amount of powder needed for the calculated dose. Use is constrained to specific populations; for example, the medicine is only permitted for pre-ruminating calves and is not approved for use in laying birds producing eggs for human consumption. The product should also not be mixed with other veterinary medicinal products without established compatibility data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Doxyral 50%


Evidence for Use in Respiratory Tract Infections

Research on Doxyral 50% (Doxycycline Hyclate) has been studied in the context of infections such as bacterial pneumonias and Chronic Respiratory Disease (CRD). The core evidence includes controlled challenge models where animals are exposed to specific bacteria, as well as field studies conducted in natural settings, designed to examine study outcomes. These research scenarios primarily examined outcomes related to systemic or functional imbalance, such as survival measured in the study groups and how clinical signs—like difficulty breathing or nasal discharge—evolved in the observed populations during the short treatment period.

The evidence base describes patterns observed when the medicine was evaluated in primary populations, including poultry, pigs, and calves. Research also examined the drug’s absorption to assess the drug concentration achieved in the blood and tissues, a finding that is a finding related to the study of symptom patterns in these specific conditions.

Evidence for Use in Gastrointestinal Tract Infections

Doxycycline was evaluated in studies focused on conditions associated with acute or disruptive episodes in the gut, such as colibacillosis and salmonellosis. The research mainly involved controlled challenge models where researchers examined the drug's effect when given orally. The key outcomes monitored in these trials included changes in gastrointestinal clinical signs (like diarrhea) and the rate of pathogen shedding.

Pharmacokinetic (PK) studies research examined how well the medicine was observed in the bloodstream after oral intake and the drug concentrations reached in the gut. Data show patterns related to how quickly the medicine entered the system and how much remained in the digestive tract, an observation related to the study of bacterial presence.

Evidence Gaps and Research Uncertainty

The majority of evidence for Doxyral 50% was observed in research exploring short-term symptom changes that focused on the period spanning the 3 to 5 days of treatment. Follow-up durations were limited in these core trials, meaning that long-term effects are not fully established.

Comparative evidence is lacking regarding how Doxycycline performs against other modern, approved alternatives in head-to-head trials. Furthermore, the issue of antimicrobial resistance is a known research gap. The data show patterns related to the presence of resistance in common pathogens, meaning the utility of the medicine may change over time. Consequently, certainty remains low when projecting the continued long-term utility of the medicine against evolving microbial threats.

Key Studies & References Community Register Record for Doxycycline (Veterinary Medicinal Product)

Frequently Asked Questions (FAQ)

Common questions about Doxyral 50% (FAQ)


Q: How long does Doxyral 50% typically take to start working?

A: Studies and official information indicate that the active ingredient begins to target and suppress bacterial growth, as well as reduce inflammation, generally within the first 24 to 48 hours. The time it takes to see clear symptomatic improvement can vary depending on the specific condition that is being addressed.


Q: Why is it called '50%'? Does that mean it’s half-strength?

A: The '50%' designation refers to the concentration of the active ingredient, Doxycycline Hyclate, within the powder formulation. Specifically, the product contains 500 milligrams of the active substance for every gram of powder. This concentration is the full, designated strength for this specific type of water-soluble formulation.


Q: Is it possible for Doxyral 50% to make me feel sick to my stomach?

A: Official prescribing information for the active ingredient, doxycycline, lists gastrointestinal effects such as nausea and vomiting as Common adverse reactions. This means that feeling sick to your stomach is one of the effects that is seen relatively often in clinical use.


Q: How long do I usually have to take Doxyral 50% for?

A: According to official administration instructions, the standard treatment duration is typically set to range from three to five consecutive days. The exact number of days is determined by the specific condition and the assessment made by a licensed professional.


Q: Can I stop taking Doxyral 50% once I start feeling better?

A: Regulatory guidance describes completing the full recommended regimen as necessary, even if signs of improvement are seen sooner. This practice is cited as helping to reduce the risk of drug-resistant bacteria developing.


Q: Does Doxyral 50% affect birth control pills?

A: Regulatory documents on drug interactions indicate that the active ingredient, doxycycline, may potentially reduce the effectiveness of some types of oral contraceptives. Official guidance describes that patients using the medicine should consider alternative or additional birth control methods.


Q: Can Doxyral 50% be taken by people with kidney issues?

A: The official product labeling states that individuals with impaired renal (kidney) function typically do not require a dosage modification. However, official information does note that caution is required, as rare cases of temporary kidney function deterioration have been reported.


Q: What happens if I miss taking a scheduled amount of Doxyral 50%?

A: General patient guidance indicates that if a scheduled amount is missed, taking it as soon as it is remembered is described. However, if it is almost time for the next scheduled amount, skipping the missed one entirely is typically advised to avoid double usage.


Q: What type of medical professional usually prescribes Doxyral 50%?

A: Given that Doxyral 50% is designated as a specialized veterinary pharmaceutical product, official document context implies that it is prescribed by a licensed veterinarian for the approved target animals.


Q: Is Doxyral 50% considered a 'broad-spectrum' medicine?

A: Yes, the active ingredient in Doxyral 50%, doxycycline, is classified in authoritative pharmacological databases as a broad-spectrum tetracycline-class antibacterial drug. This means it is generally active against a wide range of bacterial types.


Q: Does Doxyral 50% interact with common pain relievers like ibuprofen?

A: Regulatory interaction documents do not typically list a specific, clinically significant interaction between doxycycline and common pain relievers like ibuprofen. However, official labels emphasize that caution is necessary for individuals on anticoagulant (blood-thinning) therapy when combining medicines.


Q: Can Doxyral 50% cause dizziness or affect driving?

A: Dizziness is noted as an adverse effect in the official prescribing information, sometimes associated with rare nervous system conditions. If dizziness occurs, operating machinery or driving may be affected, as described in safety documents.


Q: What should be done if someone accidentally takes too much Doxyral 50%?

A: Official guidance describes that seeking immediate medical assistance is necessary if an overdose is suspected. Contacting emergency services or a local poison control center for guidance is the advised step.


Q: Is it common for Doxyral 50% to cause headaches?

A: Headache is an adverse effect noted in the official prescribing information for doxycycline. This is often mentioned alongside the need to monitor for rare, more serious nervous system conditions, such as benign intracranial hypertension.


Q: Does the time of day matter when taking Doxyral 50%?

A: While regulatory instructions do not mandate a specific time of day for administration, official guidance recommends taking the medicine with a sufficient amount of fluid. It is advised to avoid taking the medicine right before bed to help prevent the risk of irritation to the esophagus.


Q: Why is it important to complete the full recommended amount of Doxyral 50%?

A: Finishing the full recommended amount is cited in regulatory information as being essential. This practice is necessary both to ensure the resolution of the target condition and to reduce the critical public health risk of developing drug-resistant bacteria.


Q: Is Doxyral 50% a prescription-only medicine?

A: Yes, the active ingredient, doxycycline, is classified as a Prescription-Only Medicine (POM) across all major global regulatory jurisdictions. This means a licensed professional must authorize its use.

How should Doxyral 50% be stored and disposed of?

How to Store and Dispose of Doxyral 50%?

The official storage guidelines for Doxyral 50% (Doxycycline Hyclate Powder) mandate strict environmental control and specific disposal procedures.


Storage Conditions

The powder must be stored below 25°C and must not be frozen. It must be kept in a dry place and protected from light in its original container/packaging. The product must be kept out of the sight and reach of children.

Stability and Use

While the sealed product has a two-year shelf-life, the powder is only stable for 28 days after the container is opened. The medicated drinking solution prepared from the powder must be used within 24 hours.

Disposal Requirements

Unused or expired Doxyral 50% must not be disposed of via wastewater or household waste. Disposal must follow local requirements and established pharmaceutical waste collection schemes to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxyral 50% found in:

A-Z Index: